Urinary Organic Acid Esterification for GC-MS Reliability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring urinary carboxylic acids are not optimal for easy, rapid, reproducible, and reliable detection of dysbiosis of fungal or bacterial origin, due to interference from other urine constituents and lack of efficiency in isolating and quantifying these acids.
Innovation Solution
A method involving the esterification of urinary carboxylic acids with N-Methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) and trimethylchlorosilane (TMCS) in dry anhydrous acetonitrile to form trimethylsilanesters, followed by gas phase chromatography coupled with mass spectrometry for accurate measurement, allowing for the isolation and quantification of these acids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current assay techniques are used to measure urinary carboxylic acids, then measurement can be performed, but the results are not reliable and reproducible due to interference from other urine constituents
Solution Approach 1:
The patent extracts urinary carboxylic acids from the complex urine matrix by converting them to trimethylsilanester derivatives through esterification with MSTFA and TMCS. This chemical transformation separates the target analytes from interfering urine constituents, enabling reliable GC-MS measurement by eliminating matrix effects that would otherwise compromise measurement reliability.
Solution Approach 2:
The patent changes the chemical parameter of urinary carboxylic acids by esterifying them to form trimethylsilanester derivatives. This parameter change (from carboxylic acid to ester form) improves volatility and thermal stability, allowing the compounds to be analyzed by GC-MS without interference from non-volatile urine constituents, thereby resolving the reliability issue.
2Measurement precision
If complex sample preparation methods are used to isolate urinary carboxylic acids, then isolation can be achieved, but the process becomes time-consuming and difficult to reproduce
Solution Approach 1:
The patent applies preliminary chemical action by performing esterification of urinary carboxylic acids with MSTFA and TMCS before GC-MS analysis. This preliminary transformation simplifies subsequent isolation steps because the trimethylsilanester derivatives are more volatile and easier to separate from the urine matrix, reducing the complexity of the overall isolation process while maintaining precision.
Solution Approach 2:
By changing the chemical form of urinary carboxylic acids to trimethylsilanesters, the patent improves their volatility and thermal stability parameters. This parameter change enables simpler isolation techniques to achieve the same precision that would otherwise require complex preparation methods, making the process easier to operate and reproduce.
3Measurement precision
If traditional measurement methods are used, then analysis can be performed, but the detection of dysbiosis is not sensitive or accurate enough
Solution Approach 1:
The patent introduces trimethylsilanester derivatives as an intermediary form of urinary carboxylic acids. This intermediary transformation enhances the detectability of the target compounds by GC-MS, improving dysbiosis detection precision. The intermediary step (esterification) adds some complexity but enables accurate detection that traditional methods cannot achieve.
Solution Approach 2:
The patent changes the volatility and thermal stability parameters of urinary carboxylic acids through esterification to trimethylsilanesters. This parameter change makes the compounds suitable for GC-MS analysis, significantly improving detection precision for dysbiosis diagnosis despite the added analytical step.
4Quantity of substance
If multiple urinary organic acids are measured simultaneously, then comprehensive dysbiosis profiling is achieved, but the analysis becomes more complex and difficult to interpret
Solution Approach 1:
The patent applies a universal esterification reaction using MSTFA and TMCS that simultaneously transforms multiple different urinary carboxylic acids into their trimethylsilanester derivatives. This multi-functional approach allows comprehensive measurement of up to 30 different organic acids in a single GC-MS run, achieving comprehensive dysbiosis profiling without proportionally increasing analysis complexity.
Solution Approach 2:
By uniformly changing the chemical parameters of diverse urinary carboxylic acids to their trimethylsilanester forms, the patent creates a consistent set of derivatives with similar volatility and detection characteristics. This uniform parameter change simplifies the interpretation of multi-analyte data compared to measuring the original carboxylic acids with varying properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the reliable and reproducible measurement of up to 30 different urinary organic acids, improving the detection of dysbiosis by providing a clear and readable chromatogram, facilitating the diagnosis and treatment of microbial imbalances.
Implementation Method 1
esterification of said dry residue of said urinary carboxylic acids by a mixture consisting of N-Methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) and trimethylchlorosilane (TMCS) in dry anhydrous acetonitrile to form a solution comprising trimethylsilanester groups derived from said urinary carboxylic acids
Implementation Method 2
quantification by gas chromatography coupled with mass spectrometry of said trimethylsilanesters
Implementation Method 3
quantification by gas chromatography coupled with mass spectrometry of said trimethylsilanesters to obtain a measure of the quantity of said trimethylsilanesters
Data Source
AI summary
The invention relates to a dosing method comprising the following steps: supply of a pre-determined volume of a sample of urine containing derivatives of urinary carboxylic acids and constituent components of urine; production of a dry residue isolated from said constituent components of urine; esterification of the dry residue using a mixture comprising MSTFA and TMCS in acetonitrile in order to form a solution comprising trimethylsilane ester groups; dosing by gas chromatography coupled with mass spectrometry of said trimethylsilane esters in order to obtain a measurement of the quantity of trimethylsilane esters; comparison of said measured quantities with pre-determined values of quantities of trimethylsilane esters in order to dose said urinary carboxylic acids.